Shots:

• Kamada signs an agreement with two undisclosed international pharmacies to commercialize three biosimilar product candidates in Israel. The two pharmaceutical companies will be responsible for the development- manufacturing- and supply of three products
• Following the approval from EMA and IMOH- the three products are expected to be launched in Israel b/w 2022 and 2024
• The collaboration will expand Kamada’s biosimilar portfolio in Israel which already includes six products previously licensed from Alvotech

 ­ Ref: GlobeNewswire | Image: Globes English